10-Q · May 7, 2026
Kodiak Sciences reported a net loss of $58.2 million for Q1 2026, slightly worse compared to a loss of $57.5 million in the same quarter last year. R&D expenses increased to $48.5 million due to heightened clinical…
Earnings analysis · 10-Q
KOD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q presents a financially stressed clinical-stage biotechnology company: Kodiak reported a six-month net loss of $123.8 million, an accumulated deficit of $1.7 billion, and cash of $125.9 million as of…
Read full summary
The extracted 10-Q presents a financially stressed clinical-stage biotechnology company: Kodiak reported a six-month net loss of $123.8 million, an accumulated deficit of $1.7 billion, and cash of $125.9 million as of June 30, 2026. Management stated that it has no approved products, has not generated product revenue, expects continued negative operating cash flow, and faces substantial doubt regarding its ability to continue as a going concern. No quantitative guidance was provided; the principal forward-looking financial signal is the need for additional equity, debt, collaboration, or similar financing.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remain effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
No material litigation disclosed
No material litigation was pending as of the filing date: the company stated there were no claims or actions whose ultimate disposition could materially adversely affect results or financial condition as of August 13, 2026.
What to watch
-
Going-concern and funding risk
Kodiak reported a net loss of $123.8 million for the six months ended June 30, 2026 and an accumulated deficit of $1.7 billion. Management also stated that it expects continued operating losses and negative operating cash flows, creating substantial doubt about going-concern status.
-
Limited liquidity runway
Cash and cash equivalents were $125.9 million as of June 30, 2026, while the company states it has no committed source of additional capital. Kodiak may need to pause, scale back, or discontinue development programs if financing is unavailable on acceptable terms.
-
Clinical and commercialization failure risk
Kodiak has no products approved for commercial sale and has not generated revenue from product sales. Its development portfolio remains dependent on three principal candidates—tarcocimab, KSI-501, and KSI-101—while prior Phase 3 GLEAM and GLIMMER trials of tarcocimab failed to meet their primary efficacy endpoints.
-
Global manufacturing and tariff exposure
The filing highlights heightened international supply-chain and tariff exposure: drug-substance and drug-product sourcing for tarcocimab, KSI-501, and KSI-101 involves single-source suppliers across China, Japan, the United Kingdom, the United States, and Switzerland. Tariffs or trade restrictions could increase R&D costs and delay clinical timelines.
-
Data privacy and AI compliance risk
The company describes expanding data-privacy and AI-related obligations, including potential GDPR fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. It also states that use of generative AI and automated decision-making could result in regulatory investigations, litigation, or additional compliance costs.
Management's outlook
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. Management states it plans to raise additional capital through equity or debt financings, collaborations, or similar transactions, but provides no amount or timing.
Earlier filings 4
10-K · March 31, 2026
Kodiak Sciences Inc. reported its financial results for 2025, reflecting significant losses driven by increased R&D expenditures towards clinical trials for its product candidates Zenkuda, KSI-501, and KSI-101. The…
10-Q · November 13, 2025
Kodiak Sciences reported a challenging third quarter for 2025, with a significant operating loss and no revenue generated. The company continues to invest heavily in the development of its clinical pipeline but faces…
10-Q · August 13, 2025
Kodiak Sciences reported a net loss of $54.3 million for Q2 2025, compared to a loss of $45.1 million in Q2 2024. The Company maintains a strong cash position with $104.2 million as of June 30, 2025, sufficient to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.